ImmunOs Therapeutics secures USD 11M to advance cancer therapy
scroll south
ImmunOs Therapeutics has raised USD 11 million in fresh funding, strengthening its investor base as it accelerates the development of its promising cancer treatment, IOS-1002. The funding will support ongoing clinical trials, including testing the drug both on its own and in combination with Merck’s well-known cancer therapy, KEYTRUDA®. The aim is to explore how IOS-1002 could improve outcomes for cancer patients worldwide.
ImmunOs Therapeutics, a biopharmaceutical company focused on developing innovative HLA-based immune system modulators for cancer and autoimmune diseases, has announced the successful close of a USD 11 million Series C financing round. The round was led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, and BioMed Partners, with participation from new investor Double Point Ventures, alongside other returning investors. In conjunction with the round, Steve Tregay, PhD, Managing General Partner of Mission BioCapital, has joined the Company’s Board of Directors.The proceeds from Series C will be used to advance the clinical trial of ImmunOs’ lead program, IOS-1002. This trial aims to complete the Phase Ia dose escalation study, both as a monotherapy and in combination with MSD’s KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy. IOS-1002 is an innovative, multifunctional immunotherapy targeting advanced solid tumors by addressing multiple immune checkpoints, including LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1. It is designed to activate both innate and adaptive immune cells, enhancing the tumor microenvironment and potentially boosting the effectiveness of existing immunotherapies such as KEYTRUDA.
ImmunOs Therapeutics remains dedicated to furthering the development of IOS-1002 and exploring its potential to improve cancer treatment outcomes.
The Biotech startup was ranked among the TOP 100 Scale-ups from 2020 to 2023.
CEO Reinhard Ambros and Co-Founder and Chief Medical Officer Christoph Renner
ImmunOs Therapeutics AG: Drug development to antagonise various kind of tumours
ImmunOs Therapeutics AG is leading the next generation of immunotherapies by fast-tracking new discoveries to enhance combination therapies with novel human immunomodulatory proteins that have a role ... Read more
